Popular terms

Leukemia topics
Myelogenous
Myelogenous Leukemia
Proliferative
Autoimmune
Stem Cells
Breast Cancer
Rheumatoid Arthritis
Myeloid Leukemia
Acute Myelogenous Leukemia
Lymphocytic
Chronic Lymphocytic Leukemia
Lymphocytic Leukemia
Epigenetic
Multiple Myeloma
Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Leukemia patents



      
           
This page is updated frequently with new Leukemia-related patent applications.



Date/App# patent app List of recent Leukemia-related patents
01/28/16
20160024212 
 Humanized anti-hla-dr antibodies patent thumbnailHumanized anti-hla-dr antibodies
The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
Immunomedics, Inc.


01/28/16
20160024167 
 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates patent thumbnailMethods and compositions based on diphtheria toxin-interleukin-3 conjugates
The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (dt-il3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the dt-il3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3.
Scott & White Memorial Hospital


01/21/16
20160017429 
 Method for prognosing the survival of patients suffering from chronic myelomonocytic leukaemia patent thumbnailMethod for prognosing the survival of patients suffering from chronic myelomonocytic leukaemia
The present invention relates to a method of prognostic of the survival of human subject suffering from chronic myelomonocytic leukemia (cmml) based on the differential expression of six genes in a test sample of pbmc cells obtained from said human subject and in a control sample of normal cells, wherein said expression level indicates if the human subject from which the test sample has been obtained will have long-term or short-term survival.. .
Acobiom


01/14/16
20160009815 
 Methods for manipulating phagocytosis mediated by cd47 patent thumbnailMethods for manipulating phagocytosis mediated by cd47
Methods are provided to manipulate phagocytosis of cancer cells, including e.g. Leukemias, solid tumors including carcinomas, etc..
The Board Of Trustees Of The Leland Stanford Junior University


01/14/16
20160009814 
 Methods for manipulating phagocytosis mediated by cd47 patent thumbnailMethods for manipulating phagocytosis mediated by cd47
Methods are provided to manipulate phagocytosis of cancer cells, including e.g. Leukemias, solid tumors including carcinomas, etc..
The Board Of Trustees Of The Leland Stanford Junior University


01/14/16
20160009683 
 Antiproliferative compounds and methods of use thereof patent thumbnailAntiproliferative compounds and methods of use thereof
Compounds of formula i for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds.
Celgene Corporation


01/07/16
20160002629 
 Diagnostic and treatment for chronic and acute phase myeloid leukemia patent thumbnailDiagnostic and treatment for chronic and acute phase myeloid leukemia
Disclosed are methods of predicting responsiveness of a cancer cell to a tyrosine kinase inhibitor, and methods of predicting the risk of progression of a cancer cell to a more aggressive form. Also provided are methods of reducing proliferation or promoting differentiation of a cancer cell having reduced level of numb or increased level of msi.
Duke University


01/07/16
20160002354 
 Antibodies to bone marrow stromal antigen 1 patent thumbnailAntibodies to bone marrow stromal antigen 1
The invention provides antibodies which bind to the adp-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.
Oxford Biotherapeutics Ltd


01/07/16
20160002333 
 Bispecific cd33 and cd3 binding proteins patent thumbnailBispecific cd33 and cd3 binding proteins
Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
Amphivena Therapeutics, Inc.


01/07/16
20160000877 
 Compositions and methods for modulating gamma-c-cytokine activity patent thumbnailCompositions and methods for modulating gamma-c-cytokine activity
The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc


01/07/16
20160000864 

Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment


The present invention provides a pharmaceutical composition containing recombinant hemoglobin protein or tetramer or dimer or subunit for tissue oxygenation and treating cancer. The recombinant hemoglobin protein or tetramer or dimer or subunit-based therapeutic agent is also effective for treating cancer.

01/07/16
20160000829 

Methods for treating chronic lymphocytic leukemia (cll)


The present invention relates generally to the treatment of pml by infusion of activated and expanded autologous lymphocytes.. .
The Trustees Of The University Of Pennsylvania


01/07/16
20160000796 

Pharmaceutical composition for use in prevention or treatment of cancer


Abacavir, a nucleoside analogue reverse transcriptase inhibitor, has been found to exhibit an anti-cancer activity on atl cells in vitro without inhibiting dna replication of normal cells. Abacavir or a pharmaceutically acceptable derivative thereof is useful as an active ingredient of a pharmaceutical composition for use in the prevention or the treatment of cancer, in particular a cancer whose dna repair system is impaired such as breast cancer or adult t-cell leukemia..
Kyoto University


12/31/15
20150374670 

Oral dosage forms of bendamustine


In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the european pharmacopoeia in 500 ml of a dissolution medium at a ph of 1.5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, hodgkin's disease, non-hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer..
Astellas Deutschland Gmbh


12/24/15
20150368341 

Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof


Small animal models for assessing immunomodulatory effects of compounds are provided.. .
Alexion Pharmaceuticals, Inc.


12/24/15
20150368300 

Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins


The present invention relates to mll fusion proteins (e.g., af9 and enl), which activate target genes in part via recruitment of histone methyltransferase dot1l. In particular, the present invention provides the af9/enl binding site in dot1l and agents that block the protein-protein interactions between af9/enl and dot1l, therefore inhibiting the activity of dot1l, and inhibiting mll-fusion protein associated leukemia..
The Regents Of The University Of Michigan


12/24/15
20150368298 

Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)


The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


12/17/15
20150361506 

Donor kir3dl1 and hla-b subtypes and leukemia control in hla-compatible allogenic hematopoietic stem cell transplantation


This disclosure generally relates to donor selection for hematopoietic stem cell transplantation. In particular, this disclosure relates to typing kir3dl1 and hla-b alleles as basis for donor selection..
Memorial Sloan-kettering Cancer Center


12/17/15
20150361504 

Biomarker for predicting response of cll to treatment with a btk inhibitor


Disclosed herein are methods for treating an individual diagnosed with a solid tumor or a hematological malignancy, such as chronic lymphocytic leukemia (cll), for treatment with a bruton's tyrosine kinase (btk) inhibitor (e.g., ibrutinib) based on the expression level of mir-155. Also disclosed herein are methods for assessing whether an individual having a solid tumor or a hematological malignancy such as chronic lymphocytic leukemia (cll) is responsive or likely to be responsive to therapy with a btk inhibitor (e.g., ibrutinib).
Pharmacyclics Llc


12/17/15
20150359815 

Pak1 inhibition for treatment of acute myeloid leukemia and myelodysplastic syndromes


Methods are disclosed for treating acute myeloid leukemia (aml) and myelodysplastic syndromes (mds) using inhibition of p21 protein (cdc42/rac)-activated kinase (pak1).. .
Albert Einstein College Of Medicine Of Yeshiva University


12/17/15
20150359799 

Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders


The present invention relates to preventing and treating leukemia and diseases and disorders of the blood, by inhibiting canonical wnt signaling in the osteoblasts. The inhibition is accomplished by blocking specific molecules and receptors in the pathway.
The Trustees Of Columbia University In The City Of New York


12/10/15
20150354006 

Markers for acute lymphoblastic leukemia


The invention provides methods of detecting a nsd2 mutation in a cancer cell, methods cancer diagnosis and methods of screening for nsd2 inhibitors.. .
Dana-farber Cancer Institute, Inc.


12/10/15
20150352116 

Hdac inhibitor and btk inhibitor combinations


Disclosed herein are methods and compounds for treating an individual diagnosed with chronic lymphocytic leukemia (cll) or acute myeloid leukemia (aml) by administering to the individual a combination comprising ibrutinib and abexinostat. Also provided are methods for treating an ibrutinib-resistant cll or an ibrutinib-resistant aml by administering to the individual a combination comprising ibrutinib and abexinostat.
Pharmacyclics Llc


12/03/15
20150344934 

Novel high throughput assay for finding new jak3 interacting compounds, biomolecules, and inhibitors.


Janus kinase 3 is a non-receptor tyrosine kinase that mediates signals initiated by cytokines through interactions with the receptors of cytokines. Abnormal activation of jak3 was associated with human hematologic and epithelial malignancies.

12/03/15
20150344889 

Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias


Methods for assessing a pathological condition in a subject include measuring one or more markers where a difference is indicative of acute lymphoblastic leukemia (all) or a predisposition to all, uses and compositions are disclosed.. .
The Ohio State University Research Foundation


12/03/15
20150344446 

Triazolone compounds and uses thereof


And pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of formula i, or a pharmaceutically acceptable salt thereof.

12/03/15
20150344411 

Catalytic dibenzocycloheptane synthesis and allocolchicinoid synthesis


In a non-limiting embodiment, there is provided a compound of formula (i), which may permit for a method or use in treating or preventing a cancer, such as pancreatic cancer or leukemia. In one embodiment, there is also provide a method of preparing a compound of formula (ia), the method including conducting a cyclization reaction of a compound of formula (iii) to obtain a compound of formula (iv), wherein conducting the cyclization reaction comprises conducting a michael reaction in the presence of a lewis acid..
University Of Windsor


12/03/15
20150343004 

Composition for use as a support therapy for treatment of tumours, aids and leukaemia


Described in the instant application are methods and compositions for support therapy in antitumor chemotherapeutic treatments, in acquired immunodeficiency syndrome treatments and in leukemia treatments. Said methods and compositions comprise a bacterial strain belonging to the species lactobacillus pentosus and having an antiviral and an antibacterial activity, and a highly bioavailable zinc internalized in a tyndalized bacterial cell mixed with at least one rubber, and in particular an alginate and/or a gel, and in particular a gel..

12/03/15
20150342979 

Dot1l inhibitors for use in the treatment of leukemia


The present invention relates to dot1l inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which dot1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof..
Epizyme, Inc.


12/03/15
20150342961 

Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml)


Disclosed are methods and compositions for treating a patient having chronic myelogenous/myeloid leukemia (cml). The methods utilize and the compositions include prostaglandin e1 (pge1) or misoprotol..

12/03/15
20150342952 

Treatment of chronic neutrophilic leukemia (cnl) and atypical chronic myeloid leukemia (acml) by inhibitors of jak1


This invention relates to jak selective inhibitors for use in treatment of chronic neutrophilic leukemia and atypical chronic myeloid leukemia in patients.. .
Incyte Corporation


11/26/15
20150336967 

Novel benzimidazole derivatives as kinase inhibitors


The present invention relates to derivatives of benzimidazoles of formula (i) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of pim1-3- and dyrk1a-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g.
Selvita S.a.


11/26/15
20150336925 

Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors


The present invention provides for compounds that inhibit the activity of an anti-apoptotic bcl-2 family member myeloid cell leukemia-1 (mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of mcl-1 protein..
Vanderbilt University


11/19/15
20150329527 

Pyrazole linked benzimidazole conjugates and a process for preparation thereof


Pyrazole linked benzimidazole conjugates and a method for synthesis of one or more compounds having a pyrazole linked benzimidazole conjugate, particularly pyrazole linked benzimidazole conjugates that are useful as potential antitumor agents against human cancer cell lines, such as leukemia, non-small cell lung cancer, colon cancer, cns cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer. The process comprises the step of oxidative cyclization of o-phenylenediamines and 3-phenyl-1h-pyrazole-5-carbaldehydes with sodium metabisulphite in ethanol/methanol solvent system at a desired temperature for a period of time to obtain the pyrazole linked benzimidazole conjugate..
Council Of Scientific & Industrial Reseach


11/19/15
20150328273 

Extract of rehmannia glutinasa libosch for reducing blood sugar, reducing blood fat, treating leukemia, and preparation method and uses thereof


The present invention relates to a rehmannia glutinasa libosch. Extract for reducing blood glucose and lipid levels and treating hematologic diseases such as leukemia, and methods for preparing the same.

11/19/15
20150328234 

Bufalin liposome, preparation method therefor and application thereof


The present invention provides a bufalin liposome comprising a liposome bilayer and bufalin. The liposome bilayer comprises phospholipid, sterol and polyethylene glycol (peg)-derived compound.
The Fourth Military Medical University


11/12/15
20150320848 

Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)


The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


11/12/15
20150320750 

Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient


The present invention relates to a pharmaceutical composition for treating or preventing diseases caused by vascular permeability, containing imatinib, which has been conventionally used as an agent for treating chronic myeloid leukemia, or a pharmaceutically acceptable salt thereof as an active ingredient, and a method for treating disease caused by vascular permeability using the composition. The pharmaceutical composition for treating or preventing diseases caused by vascular permeability of the present invention contains imatinib, which has been conventionally used as an agent for treating chronic myeloid leukemia, as an active ingredient, so as to provide a novel use of imatinib and to be able to effectively treat or prevent diseases caused by vascular permeability, and thus may be widely applied to develop a novel agent for treating diseases caused by vascular permeability..
Ajou University Industry - Academic Cooperation Foundation


11/12/15
20150320692 

Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii


The application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii containing 80-95% of peripherial amines groups coated with maltotriose particles to make a drug for treating neoplastic proliferation diseases, particularly chronic lymphocytic leukemia.. .
Uniwersytet LÓdzki


11/05/15
20150315191 

4-position substituted pyrazolopyrimidine derivative, and use thereof in drug preparation


The invention provides a new pyrazolopyrimidine derivative and a simple, efficient and low-cost preparation method thereof. The pyrazolopyrimidine derivative of the invention has good inhibitory activity for multiple kinases, has inhibitory action on multiple solid tumors, leukemia and autoimmune diseases, provides a new effective choice for preparation of kinase inhibitors, medicines for autoimmune diseases, angiogenesis inhibitors and antitumor drugs, and has good application prospect..

11/05/15
20150315182 

Substituted reverse pyrimidine bmi-1 inhibitors


Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of b-cell specific moloney murine leukemia virus integration site 1 (bmi-1) protein and methods for their use to inhibit bmi-1 function and reduce the level of bmi-1 to treat a cancer mediated by bmi-1 are described herein.. .
Ptc Therapeutics, Inc.


11/05/15
20150313965 

Combination of lenalidomide and polypeptide construct, and uses thereof


Methods for cancer treatment include administering to a cancer patient an anti-cd38 antibody-attenuated human ifn alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise cd-38 expressing tumor cells, including b-cell lymphoma, multiple myeloma, non-hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia..
Teva Pharmaceuticals Australia Pty, Ltd


11/05/15
20150313921 

Cancer treatment methods


Methods for treatment of cancer selected from lung cancer, ovarian cancer, squamous cell carcinoma, pancreas exocrine cancer, malignant melanoma, gastric cancer, esophageal cancer, a metastases thereof, and leukemia, in a human or non-human body, comprise administrating to the body a cancer-inhibiting amount of a first compound of formula (i): or a physiologically acceptable salt thereof, wherein x, r1, r2, r3 and r4 are as defined herein.. .
Pledpharma Ab


10/29/15
20150306134 

Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii


The application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii containing 25-45% of peripheral amines groups coated with maltotriose particles to make a drug for treating neoplastic proliferation diseases, particularly chronic lymphocytic leukemia.. .
Uniwersytet LÓdzki


10/29/15
20150306070 

Use of maleimide derivatives for preventing and treating leukemia


The present invention is related to a compound of formula (i): a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of leukemia, wherein x is selected from the group consisting of n—r1, o and s; r1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; r2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and r3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.. .
Centogene Ag


10/22/15
20150299801 

Techniques for treating acute lymphoblastic leukemia (all)


The invention is based on the discovery of certain new somatic single nucleotide substitution mutations of nt5c2 gene variants found in some acute lymphoblastic leukemia (all) relapse subjects. Techniques include obtaining a biological sample taken from a subject having all, and detecting the presence or absence in the biological sample of a biomarker selected from the group consisting of an nt5c2 gene mutation, an mrna transcribed from the nt5c2 gene mutation, or a protein encoded by the nt5c2 gene mutation.
The Trustees Of Columbia University In The City New York


10/22/15
20150299336 

Therapeutic and diagnostic target gene in acute myeloid leukemia


Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an hlx gene in the subject, or an agent which inhibits activity of an expression product of the hlx gene, and also for diagnosing a subject as likely to develop a cancer comprising determining whether a stem cell obtained from the subject expresses a hlx gene at a level in excess of predetermined control level. Kits therefor are also provided..
Albert Einstein College Of Medicine Of Yeshiva University


10/22/15
20150299115 

Therapeutic compounds and compositions


Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (idh 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Agios Pharmaceuticals, Inc




Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.6963

5264

1 - 1 - 102